Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Jan 10;129(3):687–693.e1. doi: 10.1016/j.jaci.2011.12.001

Figure 1. Outline of Study Design.

Figure 1

Asthmatics with a FEV1 % predicted <80% were recruited into the study. Blood was drawn at the time of initial oral prednisone administration (Visit 1) and 30 days post oral prednisone treatment (Visit 3). The patients returned 7 days post oral prednisone treatment for a spirometry testing (Visit 2). At this visit, patients were defined as SR if less then 10% improvement in FEV1 % predicted occurred, and as SS if >12% improvement in lung volume occurred. Glucocorticoid pharmacokinetics screen was done for all SR asthma patients. Only subjects with normal prednisone pharmacokinetics profile were included in the study.